|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Neoplasms
PRALSETINIB
×| Maximum Phase: 4 |
| First Approval: 2020 |
| UNII: 1WPE73O1WV |
| Molecule Type: Small molecule |
| Molecular Formula: C27H32FN9O2 |
| Molecular Weight: 533.61 |
| AlogP: 4.2 |
| PSA: 135.53 |
| HBD: 3.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Protein farnesyltransferase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Astrocytoma; Central Nervous System Neoplasms; Colorectal Neoplasms; Gliosarcoma; Head and Neck Neoplasms; Lymphoma; Breast Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Ovarian Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Hepatitis D; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasm Metastasis; Progeria
LONAFARNIB
×| Maximum Phase: 4 |
| First Approval: 2020 |
| UNII: IOW153004F |
| Molecule Type: Small molecule |
| Molecular Formula: C27H31Br2ClN4O2 |
| Molecular Weight: 638.83 |
| AlogP: 5.91 |
| PSA: 79.53 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Growth hormone receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dwarfism, Pituitary
SOMAPACITAN
×| Maximum Phase: 4 |
| First Approval: 2020 |
| UNII: 8FOJ430U94 |
| Molecule Type: Small molecule |
| Molecular Formula: C55H97N13O19S2 |
| Molecular Weight: 1308.59 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Astrocytoma; Biliary Tract Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neurilemmoma; Optic Nerve Glioma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rectal Neoplasms; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Adenocarcinoma; Adenocarcinoma, Follicular; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Colorectal Neoplasms; Gallbladder Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma; Multiple Myeloma; Neurofibroma, Plexiform; Neurofibromatosis 1; Pancreatic Neoplasms; Sarcoma; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Neoplasms
SELUMETINIB
×| Maximum Phase: 4 |
| First Approval: 2020 |
| UNII: 6UH91I579U |
| Molecule Type: Small molecule |
| Molecular Formula: C17H15BrClFN4O3 |
| Molecular Weight: 457.69 |
| AlogP: 3.53 |
| PSA: 88.41 |
| HBD: 3.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neuroblastoma; Trypanosomiasis, African; Chagas Disease; Leishmaniasis; Trypanosomiasis
NIFURTIMOX
×| Maximum Phase: 4 |
| First Approval: 2020 |
| UNII: M84I3K7C2O |
| Molecule Type: Small molecule |
| Molecular Formula: C10H13N3O5S |
| Molecular Weight: 287.3 |
| AlogP: 0.64 |
| PSA: 106.02 |
| HBD: 0.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Calcitonin gene-related peptide type 1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Migraine Disorders
ATOGEPANT
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 7CRV8RR151 |
| Molecule Type: Small molecule |
| Molecular Formula: C29H23F6N5O3 |
| Molecular Weight: 603.52 |
| AlogP: 3.95 |
| PSA: 104.29 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Ovarian Neoplasms
PAFOLACIANINE
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: F7BD3Z4X8L |
| Molecule Type: Small molecule |
| Molecular Formula: C61H67N9O17S4 |
| Molecular Weight: 1326.52 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Endothelial PAS domain-containing protein 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Renal Insufficiency, Chronic; Carcinoma, Renal Cell; Hemangioblastoma; Neoplasms; Neuroendocrine Tumors; von Hippel-Lindau Disease
BELZUTIFAN
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 7K28NB895L |
| Molecule Type: Small molecule |
| Molecular Formula: C17H12F3NO4S |
| Molecular Weight: 383.35 |
| AlogP: 3.29 |
| PSA: 87.39 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 2; Pituitary ACTH Hypersecretion; Adrenocortical Hyperfunction; Cushing Syndrome
LEVOKETOCONAZOLE
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: R9400W927I |
| Molecule Type: Small molecule |
| Molecular Formula: C26H28Cl2N4O4 |
| Molecular Weight: 531.44 |
| AlogP: 4.21 |
| PSA: 69.06 |
| HBD: 0.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Myeloma; Neoplasms
MELPHALAN FLUFENAMIDE
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: F70C5K4786 |
| Molecule Type: Small molecule |
| Molecular Formula: C24H30Cl2FN3O3 |
| Molecular Weight: 498.43 |
| AlogP: 3.27 |
| PSA: 84.66 |
| HBD: 2.0 |
| HBA: |
| #RotB: 13.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder
VILOXAZINE
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 5I5Y2789ZF |
| Molecule Type: Small molecule |
| Molecular Formula: C13H19NO3 |
| Molecular Weight: 237.3 |
| AlogP: 1.45 |
| PSA: 39.72 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sphingosine 1-phosphate receptor Edg-1 agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Psoriasis; Immune System Diseases; Multiple Sclerosis
PONESIMOD
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 5G7AKV2MKP |
| Molecule Type: Small molecule |
| Molecular Formula: C23H25ClN2O4S |
| Molecular Weight: 460.98 |
| AlogP: 4.27 |
| PSA: 82.36 |
| HBD: 2.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ileal bile acid transporter inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cholestasis; Liver Cirrhosis, Biliary; Non-alcoholic Fatty Liver Disease; Alagille Syndrome; Biliary Atresia; Cholestasis, Intrahepatic; Pruritus
ODEVIXIBAT
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 2W150K0UUC |
| Molecule Type: Small molecule |
| Molecular Formula: C37H48N4O8S2 |
| Molecular Weight: 740.95 |
| AlogP: 5.88 |
| PSA: 174.37 |
| HBD: 5.0 |
| HBA: |
| #RotB: 17.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cytotoxic
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Chagas Disease; Infections; Leishmaniasis, Visceral; Leishmaniasis; Trypanosomiasis; Trypanosomiasis, African
FEXINIDAZOLE
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 306ERL82IR |
| Molecule Type: Small molecule |
| Molecular Formula: C12H13N3O3S |
| Molecular Weight: 279.32 |
| AlogP: 2.63 |
| PSA: 70.19 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Soluble guanylate cyclase activator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Coronary Disease; Cardiovascular Diseases; Heart Failure
VERICIGUAT
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: LV66ADM269 |
| Molecule Type: Small molecule |
| Molecular Formula: C19H16F2N8O2 |
| Molecular Weight: 426.39 |
| AlogP: 2.56 |
| PSA: 146.86 |
| HBD: 3.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Phosphotransferase pUL97 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cytomegalovirus Infections; Cytomegalovirus; Virus Diseases
MARIBAVIR
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: PTB4X93HE1 |
| Molecule Type: Small molecule |
| Molecular Formula: C15H19Cl2N3O4 |
| Molecular Weight: 376.24 |
| AlogP: 1.77 |
| PSA: 99.77 |
| HBD: 4.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ileal bile acid transporter inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alagille Syndrome; Biliary Atresia; Liver Diseases
MARALIXIBAT
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: UYB6UOF69L |
| Molecule Type: Small molecule |
| Molecular Formula: C40H56N3O4S+ |
| Molecular Weight: 674.97 |
| AlogP: 6.62 |
| PSA: 70.08 |
| HBD: 1.0 |
| HBA: |
| #RotB: 13.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia
UMBRALISIB
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 38073MQB2A |
| Molecule Type: Small molecule |
| Molecular Formula: C31H24F3N5O3 |
| Molecular Weight: 571.56 |
| AlogP: 6.66 |
| PSA: 109.06 |
| HBD: 1.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclin-dependent kinase 4 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hemangiosarcoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms
TRILACICLIB
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: U6072DO9XG |
| Molecule Type: Small molecule |
| Molecular Formula: C24H30N8O |
| Molecular Weight: 446.56 |
| AlogP: 2.72 |
| PSA: 91.21 |
| HBD: 2.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vascular endothelial growth factor receptor inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Carcinoma, Renal Cell; Neoplasms
TIVOZANIB
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 172030934T |
| Molecule Type: Small molecule |
| Molecular Formula: C22H19ClN4O5 |
| Molecular Weight: 454.87 |
| AlogP: 5.64 |
| PSA: 107.74 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Hepatocyte growth factor receptor inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Brain Neoplasms; Carcinoma, Hepatocellular; Liver Diseases; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms
TEPOTINIB
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 1IJV77EI07 |
| Molecule Type: Small molecule |
| Molecular Formula: C29H28N6O2 |
| Molecular Weight: 492.58 |
| AlogP: 4.01 |
| PSA: 96.93 |
| HBD: 0.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 integrase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections; Virus Diseases
CABOTEGRAVIR
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: HMH0132Z1Q |
| Molecule Type: Small molecule |
| Molecular Formula: C19H17F2N3O5 |
| Molecular Weight: 405.36 |
| AlogP: 0.96 |
| PSA: 100.87 |
| HBD: 2.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA polymerase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Adenovirus Infections, Human; Hemorrhagic Fever, Ebola; Adenoviridae Infections; Cytomegalovirus Infections; Smallpox; Virus Diseases
BRINCIDOFOVIR
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 6794O900AX |
| Molecule Type: Small molecule |
| Molecular Formula: C27H52N3O7P |
| Molecular Weight: 561.7 |
| AlogP: 5.25 |
| PSA: 146.13 |
| HBD: 3.0 |
| HBA: |
| #RotB: 26.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mineralocorticoid receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetic Nephropathies; Heart Failure; Cardiovascular Diseases; Renal Insufficiency, Chronic
FINERENONE
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: DE2O63YV8R |
| Molecule Type: Small molecule |
| Molecular Formula: C21H22N4O3 |
| Molecular Weight: 378.43 |
| AlogP: 2.99 |
| PSA: 110.26 |
| HBD: 2.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mu opioid receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cocaine-Related Disorders; Alcoholism; Feeding and Eating Disorders; Schizophrenia
SAMIDORPHAN
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: 7W2581Z5L8 |
| Molecule Type: Small molecule |
| Molecular Formula: C21H26N2O4 |
| Molecular Weight: 370.45 |
| AlogP: 1.25 |
| PSA: 103.86 |
| HBD: 3.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Fibroblast growth factor receptor inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Gastrointestinal Stromal Tumors; Uterine Cervical Neoplasms; Achondroplasia; Breast Neoplasms; Glioblastoma; Melanoma; Osteomalacia; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Urinary Bladder Neoplasms; Neoplasms
INFIGRATINIB
×| Maximum Phase: 4 |
| First Approval: 2021 |
| UNII: A4055ME1VK |
| Molecule Type: Small molecule |
| Molecular Formula: C26H31Cl2N7O3 |
| Molecular Weight: 560.49 |
| AlogP: 5.35 |
| PSA: 95.09 |
| HBD: 2.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Tinea Pedis; Candidiasis, Vulvovaginal
OTESECONAZOLE
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: VHH774W97N |
| Molecule Type: Small molecule |
| Molecular Formula: C23H16F7N5O2 |
| Molecular Weight: 527.4 |
| AlogP: 4.63 |
| PSA: 85.95 |
| HBD: 1.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase TYK2 negative allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Immune System Diseases; Kidney Diseases; Liver Diseases; Colitis, Ulcerative; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Lupus Nephritis; Arthritis, Psoriatic; Psoriasis
DEUCRAVACITINIB
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: N0A21N6RAU |
| Molecule Type: Small molecule |
| Molecular Formula: C20H22N8O3 |
| Molecular Weight: 422.45 |
| AlogP: 1.73 |
| PSA: 135.95 |
| HBD: 3.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Potassium-transporting ATPase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Duodenal Ulcer; Gastroesophageal Reflux; Helicobacter Infections; Stomach Ulcer
VONOPRAZAN FUMARATE
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: 4QW3X4AMLB |
| Molecule Type: Small molecule |
| Molecular Formula: C21H20FN3O6S |
| Molecular Weight: 461.47 |
| AlogP: 2.65 |
| PSA: 63.99 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
VIPIVOTIDE TETRAXETAN LUTETIUM
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: None |
| Molecule Type: Small molecule |
| Molecular Formula: C49H68LuN9O16 |
| Molecular Weight: 1214.1 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Prostanoid EP2 receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Glaucoma, Open-Angle; Ocular Hypertension
OMIDENEPAG ISOPROPYL
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: G0G0H52U6K |
| Molecule Type: Small molecule |
| Molecular Formula: C26H28N6O4S |
| Molecular Weight: 520.62 |
| AlogP: 3.42 |
| PSA: 119.31 |
| HBD: 1.0 |
| HBA: |
| #RotB: 11.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Epilepsies, Partial; Epilepsy, Complex Partial; Fragile X Syndrome; Smoking Cessation; Stress Disorders, Post-Traumatic; Tuberous Sclerosis; Status Epilepticus; Epilepsy; Epileptic Syndromes; Seizures; Spasms, Infantile
GANAXOLONE
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: 98WI44OHIQ |
| Molecule Type: Small molecule |
| Molecular Formula: C22H36O2 |
| Molecular Weight: 332.53 |
| AlogP: 4.99 |
| PSA: 37.3 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
GADOPICLENOL
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: S276568KOY |
| Molecule Type: Small molecule |
| Molecular Formula: C35H54GdN7O15 |
| Molecular Weight: 970.1 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase JAK1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Food Hypersensitivity; Kidney Diseases; Liver Diseases; Psoriasis; Dermatitis, Atopic; Eczema
ABROCITINIB
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: 73SM5SF3OR |
| Molecule Type: Small molecule |
| Molecular Formula: C14H21N5O2S |
| Molecular Weight: 323.42 |
| AlogP: 1.25 |
| PSA: 90.98 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase JAK2 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Graft vs Host Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Colorectal Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Myeloproliferative Disorders; Primary Myelofibrosis; Prostatic Neoplasms, Castration-Resistant; Severe Acute Respiratory Syndrome; Neoplasms
PACRITINIB
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: G22N65IL3O |
| Molecule Type: Small molecule |
| Molecular Formula: C28H32N4O3 |
| Molecular Weight: 472.59 |
| AlogP: 4.96 |
| PSA: 68.74 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Heart Failure; Cardiomyopathy, Hypertrophic
MAVACAMTEN
×| Maximum Phase: 4 |
| First Approval: 2022 |
| UNII: QX45B99R3J |
| Molecule Type: Small molecule |
| Molecular Formula: C15H19N3O2 |
| Molecular Weight: 273.34 |
| AlogP: 2.29 |
| PSA: 66.89 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |